2 years ago

Rosa Biotech Raises £415K Seed+ Funding for AI-Powered Liver Disease Diagnosis

  • Rosa Biotech, a University of Bristol spinout, has raised £415,000 in Seed+ funding from angel investors to accelerate pre-clinical trials for its AI-driven platform for earlier liver disease diagnosis

  • The startup aims to speed up diagnosis by combining protein design and machine learning, initially targeting non-alcoholic fatty liver disease (NAFLD)

  • The investment will kickstart Rosa's Series A funding round planned for later this year.

      • ProblemHealthcare

      "Diagnosing liver disease, particularly non-alcoholic fatty liver disease (NAFLD), often happens too late, leading to severe consequences like liver failure. Current diagnostic methods are slow and expensive, delaying treatment and putting a strain on healthcare systems."

      Solution

      "Rosa Biotech offers an AI-powered platform called Pandra that combines synthetic biology and machine learning to detect liver disease early and accurately from patient blood samples. This allows for timely intervention, potentially preventing the progression to life-threatening conditions and reducing the burden on healthcare resources."

      Covered on